Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s):  XRTX

Healthcare Biotechnology
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSXV:XRTX)

XORTX Announces Closing of US$1.1 Million Registered Direct Offering

GlobeNewswire October 29, 2025

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

GlobeNewswire October 21, 2025

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

GlobeNewswire October 20, 2025

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire October 20, 2025

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

GlobeNewswire October 17, 2025

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

GlobeNewswire September 4, 2025

XORTX Initiates IND Preparation for XORLO(TM) in Gout Program

GlobeNewswire September 3, 2025

XORTX Completes USD $114,500 Private Placement

GlobeNewswire August 8, 2025

XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

GlobeNewswire August 7, 2025
View More News ››

Opinion & Analysis (TSXV:XRTX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (TSXV:XRTX)

Using technical analysis for this stock.

It is starting a new uptrend for shareholders today,so good luck to all of you guys
coolfooldumbguy - October 17, 2025

RE:RE:Looks promising

Why do you say that?  Outstanding share count under 4 million.
Stocks2Go - May 16, 2025

RE:Looks promising

looks like a roolback coming lol
Peggy123 - April 17, 2025

Looks promising

But not sure what the future holds.Picked up a few shares in hopes it will skyrocket..
Larder111 - November 28, 2024

V.XRTX XORTX Initiates Precision Medicine Program

Pioneering Research Indicating a Role for Genetic Regulation of Xanthine Oxidase and Therapeutic Targeting of Aberrant Purine...
Stockwonder - October 9, 2024

XRTX.v Unveils 2023 Milestones and 2024 Objectives

Yesterday, the pharmaceutical company XORTX Therapeutics Inc. (XRTX.v XRTX) shared its progress in 2023 and goals for 2024, mainly...
StockHawk1 - March 20, 2024
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »